Cite
Garitaonandia I, Gonzalez R, Christiansen-Weber T, et al. Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease. Sci Rep. 2016;6:34478doi: 10.1038/srep34478.
Garitaonandia, I., Gonzalez, R., Christiansen-Weber, T., Abramihina, T., Poustovoitov, M., Noskov, A., Sherman, G., Semechkin, A., Snyder, E., & Kern, R. (2016). Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease. Scientific reports, 634478. https://doi.org/10.1038/srep34478
Garitaonandia, Ibon, et al. "Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease." Scientific reports vol. 6 (2016): 34478. doi: https://doi.org/10.1038/srep34478
Garitaonandia I, Gonzalez R, Christiansen-Weber T, Abramihina T, Poustovoitov M, Noskov A, Sherman G, Semechkin A, Snyder E, Kern R. Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease. Sci Rep. 2016 Sep 30;6:34478. doi: 10.1038/srep34478. PMID: 27686862; PMCID: PMC5055076.
Copy
Download .nbib